Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Pomel

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Bulletin Du Cancer|July 30, 2019
[Minimal invasive surgery for early stage cervical cancer. Recommendations from the GINECO surgeon's group]Christophe Pomel, Fabrice Lecuru, Eric Leblanc, et al.
The Oncologist|June 27, 2015
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyJoseph Gligorov, Xavier B Pivot, William Jacot, et al.
Lancet (London, England)|July 31, 2002
Malignant effusions and immunogenic tumour-derived exosomesFabrice Andre, Noel E C Schartz, Mojgan Movassagh, et al.
Anticancer Research|August 9, 2015
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for First Relapse of Ovarian CancerJean-Marc Classe, Olivier Glehen, Evelyne Decullier, et al.
Cancers|April 3, 2021
Adherence to French and ESGO Quality Indicators in Ovarian Cancer Surgery: An Ad-Hoc Analysis from the Prospective Multicentric CURSOC StudyMartinez Alejandra, Witold Gertych, Christophe Pomel, et al.
The Oncologist|May 11, 2025
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer networkNicolas Rippstein, Christophe Zemmour, Manuel Rodrigues, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2016
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trialRoman Rouzier, Sébastien Gouy, Frédéric Selle, et al.
Gynecologic Oncology|September 2, 2025
Diagnostic laparoscopy and cytoreduction surgery in ovarian cancer FIGO III-IV: The impact on survival of one-stage versus two-stage sequenceClémence Rebouillat, Christophe Pomel, Nicolas Bourdel, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 11, 2023
Efficacy of chemotherapy according to <i>BRCA</i> status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapseFlora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, et al.
Gynecologic Oncology|August 8, 2025
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian DatabaseClaire Chator, Marion Chevrier, Jean-Sébastien Frenel, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Bulletin Du Cancer|July 30, 2019
[Minimal invasive surgery for early stage cervical cancer. Recommendations from the GINECO surgeon's group]Christophe Pomel, Fabrice Lecuru, Eric Leblanc, et al.
The Oncologist|June 27, 2015
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyJoseph Gligorov, Xavier B Pivot, William Jacot, et al.
Lancet (London, England)|July 31, 2002
Malignant effusions and immunogenic tumour-derived exosomesFabrice Andre, Noel E C Schartz, Mojgan Movassagh, et al.
Anticancer Research|August 9, 2015
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for First Relapse of Ovarian CancerJean-Marc Classe, Olivier Glehen, Evelyne Decullier, et al.
Cancers|April 3, 2021
Adherence to French and ESGO Quality Indicators in Ovarian Cancer Surgery: An Ad-Hoc Analysis from the Prospective Multicentric CURSOC StudyMartinez Alejandra, Witold Gertych, Christophe Pomel, et al.
The Oncologist|May 11, 2025
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer networkNicolas Rippstein, Christophe Zemmour, Manuel Rodrigues, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2016
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trialRoman Rouzier, Sébastien Gouy, Frédéric Selle, et al.
Gynecologic Oncology|September 2, 2025
Diagnostic laparoscopy and cytoreduction surgery in ovarian cancer FIGO III-IV: The impact on survival of one-stage versus two-stage sequenceClémence Rebouillat, Christophe Pomel, Nicolas Bourdel, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 11, 2023
Efficacy of chemotherapy according to <i>BRCA</i> status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapseFlora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, et al.
Gynecologic Oncology|August 8, 2025
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian DatabaseClaire Chator, Marion Chevrier, Jean-Sébastien Frenel, et al.
Pageof 7